embecta Announces Definitive Agreement to Acquire Owen Mumford Holdings Limited

Rhea-AI Summary

embecta (Nasdaq: EMBC) agreed to acquire UK-based Owen Mumford for up to £150 million—£100 million upfront plus up to £50 million in performance payments tied to Aidaptus® sales over three years. The deal is expected to close in embecta’s fiscal Q3 2026, subject to approvals.

The acquisition adds drug-delivery platforms, a £69.4M FY2025 revenue base, manufacturing capabilities and global commercial reach to accelerate embecta’s transformation into a broad-based medical supplies company.

Positive

• Acquisition adds Aidaptus® drug-delivery platform
• Owen Mumford £69.4M net revenue in FY2025
• Deal expected accretive after FY2027
• Targets high-single-digit ROIC by year four
• Expands commercial reach in 100+ countries

Negative

• Upfront cash payment of £100M plus up to £50M contingent
• Transaction expected to be dilutive to adjusted net income in FY2027
• Planned financing via revolving credit borrowings increases leverage

News Market Reaction – EMBC

+2.93%

12 alerts

+2.93% News Effect

+2.7% Peak in 2 hr 22 min

+$16M Valuation Impact

$561M Market Cap

0.4x Rel. Volume

On the day this news was published, EMBC gained 2.93%, reflecting a moderate positive market reaction. Argus tracked a peak move of +2.7% during that session. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $16M to the company's valuation, bringing the market cap to $561M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Acquisition value: up to £150 million Upfront payment: £100 million Earn-out potential: up to £50 million +5 more

8 metrics

Acquisition value up to £150 million Total consideration for Owen Mumford, including earn-out

Upfront payment £100 million Cash payable at closing, subject to adjustments

Earn-out potential up to £50 million Performance-based payments tied to Aidaptus net sales

Owen Mumford revenue £69.4 million Net revenue in fiscal year 2025

Revenue concentration 80% Owen Mumford FY25 revenue from UK and U.S.

Quarterly revenue $261.2M Embecta revenue for quarter ended Dec 31, 2025

Gross margin 61.9% Quarter ended Dec 31, 2025

Debt outstanding $1,379.3M Total principal debt after $37.5M term loan reduction

Market Reality Check

Price: $8.89 Vol: Volume 715,712 vs 20-day ...

normal vol

$8.89 Last Close

Volume Volume 715,712 vs 20-day average 837,206 (relative volume 0.85x) shows no unusual trading ahead of the news. normal

Technical Shares at $8.86 are trading below the 200-day MA of $12.04 and 43.02% under the 52-week high.

Peers on Argus

EMBC fell 0.56% while peers were mixed: KMTS -7.38%, ANGO -2.16%, but STAA +4.09...

EMBC fell 0.56% while peers were mixed: KMTS -7.38%, ANGO -2.16%, but STAA +4.09% and PLSE +1.72%. This pattern points to stock-specific factors rather than a coordinated sector move.

Historical Context

5 past events · Latest: Feb 11 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 11	Board leadership changes	Neutral	-0.6%	New chairman and lead independent director following prior chair’s retirement.
Feb 05	Earnings release	Neutral	-7.8%	Reported fiscal Q1 2026 results and hosted earnings call and webcast.
Feb 05	Dividend declaration	Positive	-7.8%	Announced $0.15 quarterly cash dividend payable March 17, 2026.
Jan 22	Earnings date notice	Neutral	-9.4%	Scheduled first-quarter 2026 earnings release and investor conference call.
Dec 18	Conference participation	Neutral	+0.3%	Announced presentation at the J.P. Morgan 2026 Healthcare Conference.

Pattern Detected

Recent news—including earnings, dividend, and governance items—was often followed by flat to negative price reactions, suggesting limited short-term enthusiasm for corporate updates.

Recent Company History

Over the past few months, embecta has focused on governance, capital returns, and communication with investors. Board leadership changes on Feb 11, 2026 and multiple Form 4 equity grants preceded modest share weakness. The company reported fiscal Q1 2026 results on Feb 5, 2026, alongside a $0.15 quarterly dividend, yet the stock traded down around those dates. Earlier, embecta highlighted its participation in the J.P. Morgan 2026 Healthcare Conference. Against this backdrop, today’s announced acquisition adds a strategic expansion move to a history dominated by internal and financial updates.

Market Pulse Summary

This announcement marks a significant strategic step, adding Owen Mumford’s drug-delivery platforms ...

Analysis

This announcement marks a significant strategic step, adding Owen Mumford’s drug-delivery platforms and £69.4 million in annual revenue to embecta’s largely diabetes-focused portfolio. Management expects benefits to revenue growth from fiscal 2027 onward and targets high-single-digit return on invested capital by year four. Investors may track integration milestones, Aidaptus® adoption, and future commentary on financing under the revolving credit facility against embecta’s existing debt load of $1,379.3M and recent profitability trends.

Key Terms

auto-injector, drug-delivery devices, point-of-care testing, net sales, +4 more

8 terms

auto-injector medical

"Aidaptus® next generation auto-injector platform in the three-year period"

An auto-injector is a prefilled, handheld device that automatically inserts a needle and delivers a measured dose of medicine with minimal user steps—like a single-button epinephrine pen or insulin injector that works like an easy-to-use spray for injections. Investors care because these devices combine drug sales with a device business: approvals, patents, manufacturing quality, user safety and convenience drive recurring revenue, pricing power and regulatory or recall risk that can materially affect a company’s value.

drug-delivery devices medical

"market for drug-delivery devices supporting generic and branded therapies"

Devices designed to carry, release or target medications into the body in a controlled way, such as inhalers, injectors, patches or implantable pumps. Like a precision mail carrier that ensures the right dose gets to the right place at the right time, these products can improve treatment effectiveness, safety and patient convenience. Investors care because device design affects regulatory approval, intellectual property, recurring revenue from consumables, and the potential to differentiate therapies and expand market share.

point-of-care testing medical

"portfolio of medical devices across point-of-care testing, self-injection"

Medical tests performed at or near the site of patient care that produce rapid results without sending samples to a distant laboratory — like using a point-of-care glucose meter instead of waiting for lab work. Investors care because these tests speed treatment decisions, can lower care costs and expand the number of tests performed, creating demand for devices, supplies and software; sales hinge on accuracy, insurance coverage and regulatory approval.

net sales financial

"performance-based payments based on net sales of the Aidaptus®"

Net sales is the total money a company earns from selling its goods or services after subtracting returns, discounts, and allowances — like a store counting the cash it actually keeps after refunds and coupons. Investors use net sales to gauge true customer demand and the real size of a business’s revenue stream, since it forms the basis for profit margins, growth trends, and comparisons between companies.

operating income financial

"Gross margin improved to 61.9%, lifting operating income to $83.3M"

Operating income is the profit a company earns from its regular business activities after subtracting the costs directly related to running the business, such as wages, rent, and supplies. It shows how well the core operations are performing, ignoring income or expenses from non-regular activities like investments or one-time events. Investors use it to assess the company's efficiency and profitability from its main work.

operating cash flow financial

"Operating cash flow was $17.2M, and cash and equivalents"

Operating cash flow is the amount of money a company earns from its main business activities, like selling products or services. It shows how well the company can generate cash to pay bills, invest in growth, or return money to shareholders. This figure helps investors understand if the company’s core operations are healthy and sustainable.

revolving credit facility financial

"plans to finance the closing purchase price with the proceeds of borrowings under its revolving credit facility"

A revolving credit facility is a type of loan that a business can borrow from whenever it needs money, up to a set limit. It’s like having a credit card for companies—allowing them to borrow, pay back, and borrow again as needed, providing flexibility for managing cash flow or funding short-term expenses.

return on invested capital financial

"to generate high-single-digit return on invested capital by year four"

A percentage that shows how effectively a company turns the money invested in its business—both borrowed funds and shareholders’ equity—into operating profit after taxes. It tells investors whether a company earns more from its core operations than it costs to fund those operations; think of it like the annual return you’d expect from renovating a rental property—higher percentages mean the company uses capital more efficiently and is more likely to create value for shareholders.

AI-generated analysis. Not financial advice.

Acquisition will position embecta to participate in the rapidly expanding market for drug-delivery devices supporting generic and branded therapies and accelerate transformation into a broad‑based medical supplies company

PARSIPPANY, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“Embecta”) (Nasdaq: EMBC), a global leader in diabetes care technology, today announced that it has entered into a definitive agreement to acquire Owen Mumford Holdings Limited (“Owen Mumford”), a privately held, UK‑based innovator and manufacturer of medical devices and drug‑delivery technologies, in a transaction valued at up to £150 million. Under the terms of the agreement, embecta will acquire Owen Mumford for an upfront cash payment of £100 million at closing (subject to customary adjustments, including for closing net cash), and up to an additional £50 million in performance-based payments based on net sales of the Aidaptus^® next generation auto-injector platform in the three-year period following the closing. The transaction was unanimously approved by the embecta Board of Directors and is expected to close in embecta’s fiscal third quarter of 2026, subject to regulatory approvals and satisfaction of other closing conditions.

Owen Mumford is an innovator in drug delivery platforms and medical device technologies, serving as a trusted partner to many of the world’s largest pharmaceutical, biotech and healthcare organizations. The company’s products include a rapidly growing pharmaceutical services portfolio built on historic autoinjector success with established pharmaceutical companies and an outlook anchored by Aidaptus^® and other drug delivery devices. Owen Mumford pioneered the first plastic autoinjector and has continued to innovate and expand their product portfolio, specializing in the design and manufacture of drug delivery devices. Owen Mumford also has an established portfolio of medical devices across point-of-care testing, self-injection and pelvic health devices, with commercial channels, call points, customer relationships and geographic footprint that are highly complementary to embecta’s existing global diabetes care franchise and commercial infrastructure.

"We are extremely pleased to announce this agreement to acquire Owen Mumford, a company that has earned a global reputation for innovation, quality and patient‑centered design," said Devdatt (Dev) Kurdikar, Chairman, President and CEO of embecta. "This acquisition is expected to sustainably improve embecta’s revenue growth trajectory and will accelerate our strategic transformation into a broad-based medical supplies company which provides drug delivery platforms to pharmaceutical companies and serves chronic care patients in the obesity, diabetes, autoimmune diseases and anaphylaxis markets."

"Owen Mumford has a 70-year track-record of developing innovative solutions with long-term growth potential," said Gavin Jones, Managing Director of Owen Mumford. "With our complementary portfolios and manufacturing expertise, and by leveraging embecta’s commercial scale, we will continue to drive innovation that improves the quality of life for people living with chronic conditions and other healthcare needs while creating new opportunities for our valued customers and the Owen Mumford team."

STRATEGIC AND EXPECTED FINANCIAL BENEFITS AND TRANSACTION DETAILS

Adds a differentiated drug-delivery platform designed to support pharmaceutical partners across multiple therapeutic areas and a strong underlying intellectual property portfolio. This includes Owen Mumford’s next-generation Aidaptus^® auto-injector platform. Aidaptus^® combines an innovative patient-centric design and novel technology delivering a device with clear features and benefits. With one form factor and a single final assembly process, it streamlines large-scale manufacturing while reducing changeovers and supply chain complexity.

Expands product portfolio of chronic care devices and creates an opportunity to capitalize on embecta’s commercial presence in more than 100 countries. During fiscal year 2025, Owen Mumford generated approximately 80% of its revenue in the UK and the U.S. This creates a meaningful opportunity to leverage embecta’s global commercial infrastructure, call points and robust distribution network to broaden geographic reach and further scale these products worldwide.

Leverages core manufacturing strengths in high volume medical products by combining Owen Mumford’s device design, molding and assembly capabilities in drug-delivery systems with embecta’s large-scale manufacturing expertise, creating opportunities for operational efficiencies and expanded capacity to support future product programs.

Transaction structure and financial rationale
The transaction is structured as a share acquisition in which embecta will acquire 100% of the shares of Owen Mumford for an upfront cash payment of £100 million payable at closing, subject to customary purchase price adjustments for closing net cash and working capital, and up to an additional £50 million in performance-based payments based on net sales of Aidaptus^® in the three-year period following the closing.

Owen Mumford has a fiscal year end of September 30, and during fiscal year 2025, generated net revenue of £69.4 million.

embecta expects the acquisition to contribute to revenue growth in fiscal year 2027 and beyond; to be immaterial to embecta’s fiscal year 2027 adjusted operating income and to be accretive thereafter; to be dilutive to adjusted net income in fiscal year 2027, to be immaterial to embecta’s fiscal year 2028 adjusted net income and to be accretive thereafter; and to generate high-single-digit return on invested capital by year four, with increasing contribution thereafter.

The Company intends to discuss this acquisition in more detail on its upcoming fiscal second quarter 2026 earnings conference call, to be held on May 5, 2026.

Financing
embecta plans to finance the closing purchase price with the proceeds of borrowings under its revolving credit facility. Over the long term, embecta remains committed to paying down debt and creating financial flexibility.

Advisors
J.P. Morgan Securities LLC is serving as financial advisor and A&O Shearman LLP is serving as legal counsel to embecta.

Forvis Mazars LLP is serving as financial advisor and Mills & Reeve LLP is serving as legal counsel to Owen Mumford.

About embecta 
embecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innovative solutions, partnerships, and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, and Instagram.

About Owen Mumford
Founded in 1952 and headquartered in Oxfordshire, United Kingdom, Owen Mumford is a family-owned medical technology company with more than 70 years of innovation in healthcare device development. The company has built a strong reputation as a trusted partner to pharmaceutical and biotechnology companies, developing drug delivery technologies that support the administration of complex therapies, including its next-generation Aidaptus^® auto-injector platform designed to enable future pharmaceutical partnerships. In addition to its drug delivery capabilities, Owen Mumford also offers a portfolio of medical devices used in chronic care and point-of-care applications, including self-injection, diagnostics and other patient-focused healthcare solutions distributed in markets around the world.

SAFE HARBOR STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This press release contains express or implied "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 and other securities laws. These forward-looking statements concern our current expectations regarding strategic direction and priorities and expectations regarding our acquisition of Owen Mumford. These forward-looking statements are subject to various known and unknown risks, uncertainties and other factors, and you should not rely upon them except as statements of our present intentions and of our present expectations, which may or may not occur. When we use words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “pursue,” “will,” “goal” or similar expressions, we are making forward-looking statements. Although we believe that our forward-looking statements are based on reasonable assumptions, our expected results may not be achieved, and actual results may differ materially from our expectations. In addition, important factors that could cause actual results to differ from expectations include, among others, the risks described in our periodic reports filed with the Securities and Exchange Commission, including under the caption “Risk Factors” in our most recent Annual Report on Form 10-K, as further updated by our Quarterly Reports on Form 10-Q we have filed or will file hereafter. Except as required by law, we undertake no obligation to update any forward-looking statements appearing in this release. 

Contacts  Media Christian Glazar Sr. Director, Corporate Communications 908-821-6922 Contact Media Relations

Investors  Pravesh Khandelwal VP, Head of Investor Relations 551-264-6547  Contact IR

FAQ

What is embecta (EMBC) paying to acquire Owen Mumford and when will the deal close?

embecta is paying an upfront £100 million and up to £50 million in performance payments; closing is expected in fiscal Q3 2026. According to the company, the additional £50 million depends on Aidaptus® net sales over the three years after closing.

How did Owen Mumford perform financially before the acquisition and what does that add to EMBC?

Owen Mumford reported £69.4 million in net revenue for FY2025, providing an established revenue base. According to the company, this adds drug-delivery products, manufacturing capability and commercial channels complementary to embecta’s global diabetes franchise.

What is the expected financial impact of the Owen Mumford acquisition on embecta’s earnings?

embecta expects the deal to be immaterial to FY2027 adjusted operating income, dilutive to adjusted net income in FY2027, and accretive thereafter. According to the company, accretion is expected beyond FY2027 with increasing contribution over time.

How will embecta finance the purchase of Owen Mumford and what are the funding implications for EMBC?

embecta plans to finance the closing purchase price with borrowings under its revolving credit facility, increasing near-term leverage. According to the company, it remains committed to paying down debt and restoring financial flexibility over time.

What operational or strategic benefits does the Owen Mumford deal bring to embecta (EMBC)?

The acquisition adds a next-generation Aidaptus® auto-injector, IP and manufacturing scale to broaden product offerings. According to the company, this accelerates transformation into a broad-based medical supplies company serving chronic care and pharma partners worldwide.